CMPX · Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

80 Guest Street, Boston, MA, 02135, United States
Biotechnology
Healthcare

Market Cap

123.9M

52 Wk Range

$0.57 - $6.88

Previous Close

$0.68

Open

$0.67

Volume

1,823,734

Day Range

$0.64 - $0.73

Enterprise Value

-31.63M

Cash

163.1M

Avg Qtr Burn

-16.32M

Insider Ownership

12.47%

Institutional Own.

85.75%

Qtr Updated

Sep 30th 2026